litlas
Log inCreate account

James M. Cleary

Active 1991–2025

97
Papers
18,567
Citations
51
h-index
90
i10-index

Citations

Citations per year for James M. Cleary1992: 1 citations1995: 1 citations1997: 1 citations1998: 1 citations1999: 1 citations2001: 1 citations2002: 6 citations2003: 5 citations2004: 2 citations2005: 3 citations2006: 2 citations2007: 3 citations2008: 4 citations2010: 3 citations2011: 3 citations2012: 7 citations2013: 8 citations2014: 29 citations2015: 42 citations2016: 62 citations2017: 93 citations2018: 154 citations2019: 414 citations2020: 684 citations2021: 913 citations2022: 1,087 citations2023: 1,055 citations2024: 1,741 citations2025: 921 citations2026: 44 citations1993–1994: no citations, so these years are not shown1996: no citations, so this year is not shown2000: no citations, so this year is not shown2009: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,624 citing papers, 23.9% of this breakdownChina: 2,051 citing papers, 18.7% of this breakdownItaly: 605 citing papers, 5.5% of this breakdownJapan: 567 citing papers, 5.2% of this breakdownGermany: 553 citing papers, 5% of this breakdownUnited Kingdom: 512 citing papers, 4.7% of this breakdownFrance: 414 citing papers, 3.8% of this breakdownSpain: 348 citing papers, 3.2% of this breakdownCanada: 308 citing papers, 2.8% of this breakdownSouth Korea: 284 citing papers, 2.6% of this breakdownNetherlands: 235 citing papers, 2.1% of this breakdownAustralia: 202 citing papers, 1.8% of this breakdown
0%23.9%Other 20.7%

Institutions

Fields

  • Medicine70.8%
  • Biochemistry, Genetics and Molecular Biology20.5%
  • Immunology and Microbiology3.9%
  • Engineering2.1%
  • Neuroscience1%
  • Nursing0.4%
  • Other1.3%

Topics

  • Cancer Immunotherapy and Biomarkers6.3%
  • Ferroptosis and cancer prognosis5.4%
  • Pancreatic and Hepatic Oncology Research3.9%
  • Gastric Cancer Management and Outcomes3.4%
  • Cancer Genomics and Diagnostics3.2%
  • Cholangiocarcinoma and Gallbladder Cancer Studies3.1%
  • Other74.7%

Coauthors

All papers

Open in search
  1. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial

    Authors: Yelena Y. Janjigian, Kohei Shitara, Markus Moehler, Marcelo Garrido, Pamela Salman, Lin Shen, Lucjan Wyrwicz, Kensei Yamaguchi, Tomasz Skoczylas, Arinilda Campos Bragagnoli, Tianshu Liu, Michael Schenker, Patricio Yañez, Mustapha Tehfé, Rubén Dario Kowalyszyn, Michalis V. Karamouzis, Ricardo Brugés, Thomas Zander, Roberto Pazo-Cid, Erika Hitre, Kynan Feeney, James M. Cleary, Valerie Poulart, Dana Cullen, Ming Lei, Hong Xiao, Kaoru Kondo, Mingshun Li, Jaffer A. Ajani - The Lancet 2021 cited by 2,927

  2. Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway

    Authors: Vasanthi S. Viswanathan, Matthew J. Ryan, Harshil Dhruv, Shubhroz Gill, Ossia M. Eichhoff, Brinton Seashore‐Ludlow, Samuel D. Kaffenberger, John K. Eaton, Kenichi Shimada, Andrew J. Aguirre, Srinivas R. Viswanathan, Shrikanta Chattopadhyay, Pablo Tamayo, Wan Seok Yang, Matthew G. Rees, Sixun Chen, Žarko Bošković, Sarah Javaid, Cherrie Huang, Xiaoyun Wu, Yuen‐Yi Tseng, Elisabeth Roider, Dong Gao, James M. Cleary, Brian M. Wolpin, Jill P. Mesirov, Daniel A. Haber, Jeffrey A. Engelman, Jesse S. Boehm, Joanne Kotz, Cindy Hon, Yu Chen, William C. Hahn, Mitchell P. Levesque, John G. Doench, Michael E. Berens, Alykhan F. Shamji, Paul A. Clemons, Brent R. Stockwell, Stuart L. Schreiber - Nature 2017 cited by 2,059

  3. Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer

    Authors: Ronan J. Kelly, Jaffer A. Ajani, Jarosław Kużdżał, Thomas Zander, Eric Van Cutsem, Guillaume Piessen, Guillermo Méndez, Josephine Feliciano, Satoru Motoyama, Astrid Lièvre, Hope E. Uronis, Elena Elimova, Cecile Grootscholten, Karen Geboes, Syed Zafar, Stephanie Snow, Andrew H. Ko, Kynan Feeney, Michael Schenker, Piotr Kocoń, Jenny Zhang, Lili Zhu, Ming Lei, Prianka Singh, Kaoru Kondo, James M. Cleary, Markus Moehler - New England Journal of Medicine 2021 cited by 1,763

  4. Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer

    Authors: Srivatsan Raghavan, Peter Winter, Andrew W. Navia, Hannah L. Williams, Alan DenAdel, Kristen E. Lowder, Jennyfer Galvez-Reyes, Radha L. Kalekar, Nolawit Mulugeta, Kevin S. Kapner, Manisha Raghavan, Ashir A. Borah, Nuo Liu, Sara A. Väyrynen, Andressa Dias Costa, Raymond W.S. Ng, Junning Wang, Emma K. Hill, Dorisanne Ragon, Lauren K. Brais, Alex M. Jaeger, Liam F. Spurr, Yvonne Y. Li, Andrew D. Cherniack, Matthew A. Booker, Elizabeth F. Cohen, Michael Tolstorukov, Isaac Wakiro, Asaf Rotem, Bruce E. Johnson, James M. McFarland, Ewa Sicińska, Tyler Jacks, Ryan J. Sullivan, Geoffrey I. Shapiro, Thomas E. Clancy, Kimberly Perez, Douglas A. Rubinson, Kimmie Ng, James M. Cleary, Lorin Crawford, Scott R. Manalis, Jonathan A. Nowak, Brian M. Wolpin, William C. Hahn, Andrew J. Aguirre, Alex K. Shalek - Cell 2021 cited by 614

  5. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study

    Authors: Ghassan K. Abou‐Alfa, Teresa Macarulla, Milind Javle, Robin Kate Kelley, Sam Joseph Lubner, Jorge Adeva, James M. Cleary, Daniel V.T. Catenacci, Mitesh J. Borad, John Bridgewater, William Proctor Harris, Adrian Murphy, Do‐Youn Oh, Jonathan Whisenant, Maeve A. Lowery, Lipika Goyal, Rachna T. Shroff, Anthony B. El-Khoueiry, Bin Fan, Bin Wu, Christina X. Chamberlain, Liewen Jiang, Camelia Gliser, Shuchi S. Pandya, Juan W. Valle, Andrew X. Zhu - The Lancet Oncology 2020 cited by 1,075

  6. Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer

    Authors: Kohei Shitara, Jaffer A. Ajani, Markus Moehler, Marcelo Garrido, Carlos Gallardo, Lin Shen, Kensei Yamaguchi, Lucjan Wyrwicz, Tomasz Skoczylas, Arinilda Campos Bragagnoli, Tianshu Liu, Mustapha Tehfé, Elena Elimova, Ricardo Brugés, Thomas Zander, Sérgio de Azevedo, Rubén Dario Kowalyszyn, Roberto Pazo-Cid, Michael Schenker, James M. Cleary, Patricio Yañez, Kynan Feeney, Michalis V. Karamouzis, Valerie Poulart, Ming Lei, Hong Xiao, Kaoru Kondo, Mingshun Li, Yelena Y. Janjigian - Nature 2022 cited by 442

  7. Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation

    Authors: Andrew X. Zhu, Teresa Macarulla, Milind Javle, Robin Kate Kelley, Sam Joseph Lubner, Jorge Adeva, James M. Cleary, Daniel V.T. Catenacci, Mitesh J. Borad, John Bridgewater, William Proctor Harris, Adrian Murphy, Do‐Youn Oh, Jonathan Whisenant, Maeve A. Lowery, Lipika Goyal, Rachna T. Shroff, Anthony B. El-Khoueiry, Christina X. Chamberlain, Elia Aguado-Fraile, Sung Choe, Bin Wu, Hua Liu, Camelia Gliser, Shuchi S. Pandya, Juan W. Valle, Ghassan K. Abou‐Alfa - JAMA Oncology 2021 cited by 473

  8. Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer

    Authors: Robert J. Mayer, Eric Van Cutsem, Alfredo Falcone, Takayuki Yoshino, Rocio García‐Carbonero, Nobuyuki Mizunuma, Kentaro Yamazaki, Yasuhiro Shimada, Josep Tabernero, Yoshito Komatsu, Alberto Sobrero, Éveline Boucher, Marc Peeters, Ben Tran, Heinz‐Josef Lenz, Alberto Zaniboni, Howard S. Höchster, James M. Cleary, Hans Prenen, Fabio Benedetti, Hirokazu Mizuguchi, Lukas Makris, Masanobu Ito, Atsushi Ohtsu - New England Journal of Medicine 2015 cited by 1,431

  9. Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids

    Authors: Russell W. Jenkins, Amir Reza Aref, Patrick H. Lizotte, Elena V. Ivanova, Susanna Stinson, Chensheng W. Zhou, Michaela Bowden, Jiehui Deng, Hongye Liu, Diana Miao, Meng Xiao He, William H. Walker, Gao Zhang, Tian Tian, Chaoran Cheng, Zhi Wei, Sangeetha Palakurthi, Mark Bittinger, Hans Vitzthum, Jong Wook Kim, Ashley A. Merlino, Max M. Quinn, Chandrasekar Venkataramani, Joshua A. Kaplan, Andrew Portell, Prafulla C. Gokhale, Bart Phillips, Alicia Smart, Asaf Rotem, Robert E. Jones, Lauren Keogh, María Anguiano, Lance Stapleton, Zhiheng Jia, Michal Barzily-Rokni, Israel Cañadas, Tran C. Thai, Marc R. Hammond, Raven Vlahos, Eric S. Wang, Hua Zhang, Shuai Li, Glenn J. Hanna, Wei Huang, Mai P. Hoang, Adriano Piris, Jean-Pierre Eliane, Anat Stemmer‐Rachamimov, Lisa Cameron, Mei-Ju Su, Parin Shah, Benjamin Izar, Manisha Thakuria, Nicole R. LeBoeuf, Guilherme Rabinowits, Viswanath Gunda, Sareh Parangi, James M. Cleary, Brian C. Miller, Shunsuke Kitajima, Rohit Thummalapalli, Benchun Miao, Thanh U. Barbie, Vivek Sivathanu, Joshua A. Wong, William G. Richards, Raphael Bueno, Charles H. Yoon, Juan J. Miret, Meenhard Herlyn, Levi A. Garraway, Eliezer M. Van Allen, Gordon J. Freeman, Paul T. Kirschmeier, Jochen H. Lorch, Patrick A. Ott, F. Stephen Hodi, Keith T. Flaherty, Roger D. Kamm, Genevieve M. Boland, Kwok‐Kin Wong, David Dornan, Cloud P. Paweletz, David A. Barbie - Cancer Discovery 2017 cited by 585

  10. Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer

    Authors: Urszula N. Wasko, Jingjing Jiang, Tanner C. Dalton, Álvaro Curiel‐García, A. Cole Edwards, Yingyun Wang, Bianca J. Lee, Margo Orlen, Sha Tian, Clint A. Stalnecker, Kristina Drizyte‐Miller, Marie Ménard, Julien Dilly, Stephen A. Sastra, Carmine F. Palermo, Marie C. Hasselluhn, Amanda R. Decker-Farrell, Stephanie Chang, Lingyan Jiang, Xing Wei, Yu Chi Yang, Ciara Helland, Haley Courtney, Yevgeniy Gindin, Karl Muonio, Ruiping Zhao, Samantha B. Kemp, Cynthia Clendenin, Rina Sor, William P. Vostrejs, Priya S. Hibshman, Amber M. Amparo, Connor J. Hennessey, Matthew G. Rees, Melissa M. Ronan, Jennifer A. Roth, Jens Brodbeck, Lorenzo Tomassoni, Basil Bakir, Nicholas D. Socci, Laura E. Herring, Natalie K. Barker, Junning Wang, James M. Cleary, Brian M. Wolpin, John A. Chabot, Michael D. Kluger, Gulam A. Manji, Kenneth Y. Tsai, Miroslav Sekulic, Stephen M. Lagana, Andrea Califano, Elsa Quintana, Zhengping Wang, Jacqueline A.M. Smith, Matthew Holderfield, David Wildes, Scott W. Lowe, Michael A. Badgley, Andrew J. Aguirre, Robert H. Vonderheide, Ben Z. Stanger, Timour Baslan, Channing J. Der, Mallika Singh, Kenneth P. Olive - Nature 2024 cited by 175

  11. First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial

    Authors: Yelena Y. Janjigian, Jaffer A. Ajani, Markus Moehler, Lin Shen, Marcelo Garrido, Carlos Gallardo, Lucjan Wyrwicz, Kensei Yamaguchi, James M. Cleary, Elena Elimova, Michalis V. Karamouzis, Ricardo Brugés, Tomasz Skoczylas, Arinilda Campos Bragagnoli, Tianshi Liu, Mustapha Tehfé, Thomas Zander, Rubén Dario Kowalyszyn, Roberto Pazo-Cid, Michael Schenker, Kynan Feeny, Rui Wang, Ming Lei, Clara Chen, Raheel Nathani, Kohei Shitara - Journal of Clinical Oncology 2024 cited by 216

  12. Spatially Resolved Single-Cell Assessment of Pancreatic Cancer Expression Subtypes Reveals Co-expressor Phenotypes and Extensive Intratumoral Heterogeneity

    Authors: Hannah L. Williams, Andressa Dias Costa, Jinming Zhang, Srivatsan Raghavan, Peter Winter, Kevin S. Kapner, Scott P. Ginebaugh, Sara A. Väyrynen, Juha P. Väyrynen, Chen Yuan, Andrew W. Navia, Junning Wang, Annan Yang, Timothy L. Bosse, Radha L. Kalekar, Kristen E. Lowder, Mai Chan Lau, Dalia Elganainy, Vicente Morales-Oyarvide, Douglas A. Rubinson, Harshabad Singh, Kimberly Perez, James M. Cleary, Thomas E. Clancy, Jiping Wang, Joseph D. Mancias, Lauren K. Brais, Emma R. Hill, Margaret M. Kozak, David C. Linehan, Richard F. Dunne, Daniel T. Chang, Albert C. Koong, Aram F. Hezel, William C. Hahn, Alex K. Shalek, Andrew J. Aguirre, Jonathan A. Nowak, Brian M. Wolpin - Cancer Research 2022 cited by 90

  13. Phase II and Pharmacodynamic Study of Autophagy Inhibition Using Hydroxychloroquine in Patients With Metastatic Pancreatic Adenocarcinoma

    Authors: Brian M. Wolpin, Douglas A. Rubinson, Xiaoxu Wang, Jennifer A. Chan, James M. Cleary, Peter C. Enzinger, Charles S. Fuchs, Nadine J. McCleary, Jeffrey A. Meyerhardt, Kimmie Ng, Deborah Schrag, Allison L. Sikora, Beverly Spicer, Leah Killion, Harvey J. Mamon, Alec C. Kimmelman - The Oncologist 2014 cited by 372

  14. Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine

    Authors: Andrew J. Aguirre, Jonathan A. Nowak, Nicholas D. Camarda, Richard A. Moffitt, Arezou A. Ghazani, Mehlika Hazar-Rethinam, Srivatsan Raghavan, Jaegil Kim, Lauren K. Brais, Dorisanne Ragon, Marisa W. Welch, Emma Reilly, Devin McCabe, Lori Marini, Kristin Anderka, Karla Helvie, Nelly Oliver, Ana Babić, Annacarolina da Silva, Brandon Nadres, Emily E. Van Seventer, Heather A. Shahzade, Joseph P. St. Pierre, Kelly P. Burke, Thomas E. Clancy, James M. Cleary, Leona A. Doyle, Kunal Jajoo, Nadine J. McCleary, Jeffrey A. Meyerhardt, Janet E. Murphy, Kimmie Ng, Anuj Patel, Kimberly Perez, Michael H. Rosenthal, Douglas A. Rubinson, Marvin Ryou, Geoffrey I. Shapiro, Ewa Sicińska, Stuart G. Silverman, Rebecca J. Nagy, Richard B. Lanman, Deborah Knoerzer, Dean J. Welsch, Matthew B. Yurgelun, Charles S. Fuchs, Levi A. Garraway, Gad Getz, Jason L. Hornick, Bruce E. Johnson, Matthew H. Kulke, Robert J. Mayer, Jeffrey W. Miller, Paul B. Shyn, David A. Tuveson, Nikhil Wagle, Jen Jen Yeh, William C. Hahn, Ryan B. Corcoran, Scott L. Carter, Brian M. Wolpin - Cancer Discovery 2018 cited by 369

  15. Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors

    Authors: Albiruni RA Razak, James M. Cleary, Víctor Moreno, Michael Boyer, Emiliano Calvo Aller, William J. Edenfield, Jeanne Tie, R. Donald Harvey, Annemie Rutten, Manish A. Shah, Anthony J. Olszanski, Dirk Jäger, Nehal J. Lakhani, David P. Ryan, Erik Rasmussen, Gloria Juan, Hansen Wong, Neelesh Soman, Marie-Anne Damiette Smit, Dirk Nagorsen, Kyriakos P. Papadopoulos - Journal for ImmunoTherapy of Cancer 2020 cited by 118

  16. Biomarker-Guided Development of DNA Repair Inhibitors

    Authors: James M. Cleary, Andrew J. Aguirre, Geoffrey I. Shapiro, Alan D. D’Andrea - Molecular Cell 2020 cited by 230

  17. Institutional implementation of clinical tumor profiling on an unselected cancer population

    Authors: Lynette M. Sholl, T. Khanh, Priyanka Shivdasani, Ethan Cerami, Adrian M. Dubuc, Frank C. Kuo, Elizabeth P. Garcia, Yonghui Jia, Phani K. Davineni, Ryan Abo, Trevor J. Pugh, Paul Van Hummelen, Aaron R. Thorner, Matthew D. Ducar, Alice H. Berger, Mizuki Nishino, Katherine A. Janeway, Alanna J. Church, Marian H. Harris, Lauren L. Ritterhouse, Joshua D. Campbell, Vanesa Rojas‐Rudilla, Azra H. Ligon, Shakti Ramkissoon, James M. Cleary, Ursula A. Matulonis, Geoffrey R. Oxnard, Richard C. Chao, Vanessa Tassell, James G. Christensen, William C. Hahn, Philip W. Kantoff, David J. Kwiatkowski, Bruce E. Johnson, Matthew Meyerson, Levi A. Garraway, Geoffrey I. Shapiro, Barrett J. Rollins, Neal I. Lindeman, Laura E. MacConaill - JCI Insight 2016 cited by 448

  18. Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers

    Authors: James J. Harding, Sarina A. Piha‐Paul, Ronak Shah, Jessica Murphy, James M. Cleary, Geoffrey I. Shapiro, David I. Quinn, Irene Braña, Víctor Moreno, Mitesh J. Borad, Sherene Loi, Iben Spanggaard, Haeseong Park, James M. Ford, Mónica Arnedos, Salomon M. Stemmer, Christelle de la Fouchardière, Christos Fountzilas, Jie Zhang, Daniel DiPrimeo, Casey Savin, S. Duygu Selçuklu, Michael F. Berger, Lisa D. Eli, Funda Meric‐Bernstam, Komal Jhaveri, David B. Solit, Ghassan K. Abou‐Alfa - Nature Communications 2023 cited by 85

  19. Mutant IDH1 inhibition induces dsDNA sensing to activate tumor immunity

    Authors: Meng‐Ju Wu, Hiroshi Kondo, Ashwin V. Kammula, Lei Shi, Yi Xiao, Sofiene Dhiab, Qin Xu, Chloe J. Slater, Omar I. Avila, Joshua Merritt, Hiroyuki Kato, Prabhat Kattel, Jonathan Sussman, Ilaria Gritti, Jason Eccleston, Yi Sun, Hyo Min Cho, Kira E. Olander, Takeshi Katsuda, Diana D. Shi, Milan R. Savani, Bailey Smith, James M. Cleary, Raúl Mostoslavsky, Vindhya Vijay, Yosuke Kitagawa, Hiroaki Wakimoto, Russell W. Jenkins, Kathleen B. Yates, Jihye Paik, Anna M. Tassinari, Hatice D. Saatcioglu, Adriana E. Tron, Wilhelm Haas, Daniel P. Cahill, Samuel K. McBrayer, Robert T. Manguso, Nabeel Bardeesy - Science 2024 cited by 89

  20. Secondary IDH1 resistance mutations and oncogenic IDH2 mutations cause acquired resistance to ivosidenib in cholangiocarcinoma

    Authors: James M. Cleary, Betty Rouaisnel, Antoine Daina, Srivatsan Raghavan, Lauren A. Roller, Brandon M. Huffman, Harshabad Singh, Patrick Y. Wen, Nabeel Bardeesy, Vincent Zoete, Brian M. Wolpin, Julie-Aurore Losman - npj Precision Oncology 2022 cited by 78

  21. A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-Dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer

    Authors: Arta M. Monjazeb, Anita Giobbie‐Hurder, Ana Lako, Emily M. Thrash, Ryan Brennick, Katrina Kao, Claire Manuszak, Ryan D. Gentzler, Anteneh Tesfaye, Salma K. Jabbour, Olatunji B. Alese, Osama E. Rahma, James M. Cleary, Elad Sharon, Harvey J. Mamon, May Cho, Howard Streicher, Helen X. Chen, Mansoor M. Ahmed, Adrián Mariño‐Enríquez, Seunghee Kim‐Schulze, Sacha Gnjatic, Emanual Maverakis, Alina I. Marusina, Alexander A. Merleev, Mariano Severgnini, Kathleen L. Pfaff, James Lindsay, Jason L. Weirather, Srinika Ranasinghe, Alexander Spektor, Scott J. Rodig, F. Stephen Hodi, Jonathan D. Schoenfeld - Clinical Cancer Research 2021 cited by 101

  22. Neoadjuvant Chemotherapy Is Associated with Altered Immune Cell Infiltration and an Anti-Tumorigenic Microenvironment in Resected Pancreatic Cancer

    Authors: Andressa Dias Costa, Sara A. Väyrynen, Akhil Chawla, Jinming Zhang, Juha P. Väyrynen, Mai Chan Lau, Hannah L. Williams, Chen Yuan, Vicente Morales-Oyarvide, Dalia Elganainy, Harshabad Singh, James M. Cleary, Kimberly Perez, Kimmie Ng, William A. Freed-Pastor, Joseph D. Mancias, Stephanie K. Dougan, Jiping Wang, Douglas A. Rubinson, Richard F. Dunne, Margaret M. Kozak, Lauren K. Brais, Emma Reilly, Thomas E. Clancy, David C. Linehan, Daniel T. Chang, Aram F. Hezel, Albert C. Koong, Andrew J. Aguirre, Brian M. Wolpin, Jonathan A. Nowak - Clinical Cancer Research 2022 cited by 76

  23. A phase I/II study of rovalpituzumab tesirine in delta-like 3—expressing advanced solid tumors

    Authors: Aaron S. Mansfield, David S. Hong, Christine L. Hann, Anna F. Farago, Himisha Beltran, Saiama N. Waqar, Andrew Hendifar, Lowell Anthony, Matthew H. Taylor, Alan H. Bryce, Scott T. Tagawa, Karl D. Lewis, Jiaxin Niu, Christine H. Chung, James M. Cleary, M. Rossi, Carrianne Ludwig, Ricardo Santoyo Valenzuela, Yan Luo, Rahul Aggarwal - npj Precision Oncology 2021 cited by 74

  24. Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study

    Authors: Tanios Bekaii‐Saab, Fang‐Shu Ou, Daniel H. Ahn, Patrick M. Boland, Kristen K. Ciombor, Erica N. Heying, Travis Dockter, Nisha L. Jacobs, Boris Pasche, James M. Cleary, Jeffrey P. Meyers, Rodwige J. Desnoyers, Jeannine S. McCune, Katrina S. Pedersen, Afsaneh Barzi, E. Gabriela Chiorean, Jeffrey A. Sloan, Mario E. Lacouture, Heinz‐Josef Lenz, Axel Grothey - The Lancet Oncology 2019 cited by 284